Renal · Mineral and Bone Disorder
The facts most likely to be tested
The most common cause of secondary hyperparathyroidism is chronic kidney disease (CKD) due to decreased 1,25-dihydroxyvitamin D production and phosphate retention.
Laboratory findings characteristically show elevated parathyroid hormone (PTH), low or low-normal serum calcium, and hyperphosphatemia.
Chronic hyperphosphatemia directly stimulates the parathyroid glands and decreases calcitriol synthesis, further exacerbating PTH secretion.
Patients often present with renal osteodystrophy, which encompasses a spectrum of bone pathology including osteitis fibrosa cystica.
The initial management strategy focuses on dietary phosphate restriction and the use of phosphate binders such as sevelamer or calcium acetate.
Vitamin D analogs like calcitriol or paricalcitol are indicated to suppress PTH levels in patients with persistent elevation.
Calcimimetics such as cinacalcet act as allosteric modulators of the calcium-sensing receptor to decrease PTH secretion without increasing serum calcium.
Vignette unlocked
A 58-year-old male with a history of stage 4 chronic kidney disease presents for a routine follow-up. He reports generalized bone pain and recent muscle weakness. Laboratory studies reveal a serum calcium of 8.2 mg/dL (normal 8.5–10.5), a serum phosphate of 5.8 mg/dL (normal 2.5–4.5), and an elevated intact PTH level of 450 pg/mL (normal 10–65). His 25-hydroxyvitamin D level is within normal limits.
What is the most appropriate initial pharmacologic intervention to address the underlying pathophysiology of his elevated PTH?
Phosphate binders
The patient has secondary hyperparathyroidism due to CKD; the first-line management is to control hyperphosphatemia using phosphate binders to prevent further stimulation of the parathyroid glands.
Full handout
High yield triage
Etiology / Epidemiology
Primarily caused by chronic kidney disease (CKD) leading to phosphate retention and vitamin D deficiency.
Clinical Manifestations
Often asymptomatic; look for renal osteodystrophy and bone pain or fractures.
Diagnosis
Elevated PTH with low or normal calcium and elevated phosphate.
Treatment
Manage underlying cause; phosphate binders and vitamin D analogs are first-line.
Prognosis
Risk of vascular calcification and cardiovascular mortality if left untreated.
Full handout
Epidemiology & Etiology
Most common in patients with CKD stage 3-5 due to impaired renal phosphate excretion. Also seen in severe vitamin D deficiency or malabsorption syndromes. It represents a compensatory response to hypocalcemia.
Pertinent Anatomy
The parathyroid glands respond to serum ionized calcium levels via the calcium-sensing receptor. In chronic disease, the glands undergo hyperplasia to maintain calcium homeostasis.
Pathophysiology
Decreased GFR leads to hyperphosphatemia, which directly stimulates PTH secretion and suppresses 1-alpha-hydroxylase. Reduced active 1,25-dihydroxyvitamin D further decreases intestinal calcium absorption. The resulting chronic hypocalcemia triggers persistent parathyroid gland hyperplasia.
Clinical Manifestations
Patients often present with renal osteodystrophy, manifesting as bone pain, proximal muscle weakness, and increased fracture risk. Calciphylaxis is a rare but life-threatening complication involving skin necrosis. Chronic elevation leads to metastatic calcification of soft tissues and vessels.
Diagnosis
The gold standard is the biochemical profile: elevated intact PTH, low-to-normal serum calcium, and elevated serum phosphate. Radiographs may show subperiosteal resorption or a salt-and-pepper skull appearance. DEXA scan is used to assess bone mineral density.
Treatment
First-line therapy includes phosphate binders (e.g., calcium acetate or sevelamer) to lower serum phosphate. Vitamin D analogs (e.g., calcitriol) are used to suppress PTH synthesis. Avoid aluminum-based binders due to neurotoxicity. If refractory, calcimimetics (cinacalcet) may be used to increase receptor sensitivity.
Prognosis
Long-term outcomes depend on strict control of calcium-phosphate product to prevent cardiovascular events. Patients require regular monitoring of PTH and mineral levels to guide therapy adjustments.
Differential Diagnosis
Primary Hyperparathyroidism: elevated PTH with hypercalcemia
Vitamin D Deficiency: low PTH and low calcium
Pseudohypoparathyroidism: elevated PTH with end-organ resistance
Multiple Myeloma: hypercalcemia with suppressed PTH
Malignancy: hypercalcemia with suppressed PTH